CSF and blood soluble TREM2 (sTREM2) levels have been found to increase at early stage of Alzheimer's disease (AD). The relationships between sTREM2, AD-related biomarkers, and other neuroinflammation biomarkers remain unclear. Moreover, the impact of rare variants in TREM2 gene (R47H/R62H), which are associated with increased risk of AD, on plasma sTREM2 has not been elucidated.
Objective
Investigate the association of plasma sTREM2 levels with brain amyloid-β (Aβ) load and AD-related blood biomarkers, i.e., phosphorylated tau (pTau)-181, pTau-231, GFAP, NFL, and other neuroinflammation and peripheral inflammation markers in cognitively normal (CN) older adults at risk of AD (CN Aβ+) compared to CN Aβ-, including the effect of AD-linked TREM2 rare variants.
Methods
Plasma sTREM2 concentrations were measured by MesoScale Discovery (MSD) assay from the KARVIAH cohort. Participants underwent cognitive tests and PET amyloid imaging. Genetic data and blood biomarkers were included for correlation analysis. Associations with plasma sTREM2 were investigated upon stratification by PET-Aβ load SUVR ((CN Aβ- (n = 65) and CN Aβ+ (n = 35)) as the main analysis. A subgroup analysis based on the TREM2 R47H and R62H genotype was conducted as exploratory analysis.
Results
Plasma sTREM2 positively correlated with plasma pTau181, and pTau231 in CN Aβ+ group. Plasma sTREM2 positively correlated with serum microglial kynurenine pathway metabolites. Plasma sTREM2 and brain Aβ load were higher in R47H TREM2 carriers compared to non-carriers.
Conclusions
Our findings suggest plasma sTREM2 relates to downstream tau processes in amyloid-positive individuals, providing novel insights into the roles of peripheral TREM2 signaling that reflects microglial activity in early AD neuropathological development.
JonssonTStefanssonHSteinbergS, et al.Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med2013; 368: 107–116.
2.
GuerreiroRWojtasABrasJ, et al.TREM2 Variants in Alzheimer's disease. N Engl J Med2013; 368: 117–127.
3.
CarmonaSZahsKWuE, et al.The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders. Lancet Neurol2018; 17: 721–730.
4.
SongWMJoshitaSZhouY, et al.Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med2018; 215: 745–760.
5.
SimsRvan der LeeSJNajAC, et al.Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet2017; 49: 1373–1384.
6.
KorvatskaOLeverenzJBJayadevS, et al.R47h variant of TREM2 associated with Alzheimer disease in a large late-onset family: clinical, genetic, and neuropathological study. JAMA Neurol2015; 72: 920–927.
Boza-SerranoARuizRSanchez-VaroR, et al.Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer's disease. Acta Neuropathol2019; 138: 251–273.
9.
ZhongLWangZWangD, et al.Amyloid-beta modulates microglial responses by binding to the triggering receptor expressed on myeloid cells 2 (TREM2). Mol Neurodegener2018; 13: 15.
10.
PiccioLDemingYDel-AguilaJL, et al.Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol2016; 131: 925–933.
11.
AshtonNJSuarez-CalvetMHeslegraveA, et al.Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. Alzheimers Res Ther2019; 11: 94.
12.
WunderlichPGlebovKKemmerlingN, et al.Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem2013; 288: 33027–33036.
13.
Suarez-CalvetMKleinbergerGAraque CaballeroMA, et al.sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med2016; 8: 466–476.
14.
RauchmannBSSadlonAPerneczkyR, et al.Soluble TREM2 and inflammatory proteins in Alzheimer's disease cerebrospinal fluid. J Alzheimers Dis2020; 73: 1615–1626.
15.
WangRZhanYZhuW, et al.Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis. Front Aging Neurosci2024; 16: 1407980.
16.
HenjumKAlmdahlISArskogV, et al.Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther2016; 8: 17.
17.
Suarez-CalvetMAraque CaballeroMAKleinbergerG, et al.Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci Transl Med2016; 8: 369ra178.
18.
Morenas-RodriguezELiYNuscherB, et al.Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurol2022; 21: 329–341.
19.
HeslegraveAHeywoodWPatersonR, et al.Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener2016; 11: 3.
20.
Suarez-CalvetMMorenas-RodriguezEKleinbergerG, et al.Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. Mol Neurodegener2019; 14: 1.
21.
DuSHZhangWYueX, et al.Role of CXCR1 and interleukin-8 in methamphetamine-induced neuronal apoptosis. Front Cell Neurosci2018; 12: 230.
22.
OharaTHataJTanakaM, et al.Serum soluble triggering receptor expressed on myeloid cells 2 as a biomarker for incident dementia: the hisayama study. Ann Neurol2019; 85: 47–58.
23.
NabizadehFSeyedmirzaeiHKaramiS. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study. Sci Rep2024; 14: 15318.
24.
SchulzIKruseNGeraRG, et al.Systematic assessment of 10 biomarker candidates focusing on alpha-synuclein-related disorders. Mov Disord2021; 36: 2874–2887.
25.
LanGLiAGonzalez-OrtizF, et al.Higher plasma soluble TREM2 correlates with reduced cerebral tau accumulation in Alzheimer's disease. Mol Psychiatry2025; 30: 3988–3997.
26.
GoozeeKChatterjeePJamesI, et al.Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease. Sci Rep2017; 7: 676.
27.
NasreddineZSPhillipsNChertkowH. Normative data for the montreal cognitive assessment (MoCA) in a population-based sample. Neurology2012; 78: 765–766. author reply 766.
28.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
29.
FolsteinMFFolsteinSEMcHughPR. Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
30.
ZhouLSalvadoODoreV, et al.MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS One2014; 9: e84777.
31.
BourgeatPVillemagneVLDoreV, et al.Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging2015; 36: S159–S166.
32.
GoozeeKChatterjeePJamesI, et al.Elevated plasma ferritin in elderly individuals with high neocortical amyloid-beta load. Mol Psychiatry2018; 23: 1807–1812.
33.
ChatterjeePGoozeeKLimCK, et al.Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-beta load: a pilot study. Sci Rep2018; 8: 8008.
34.
ChatterjeePGoozeeKSohrabiHR, et al.Association of plasma neurofilament light chain with neocortical amyloid-beta load and cognitive performance in cognitively normal elderly participants. J Alzheimers Dis2018; 63: 479–487.
35.
RosenthalSLBamneMNWangX, et al.More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. Neurobiol Aging2015; 36: 2443 e2421–2446.
36.
ChatterjeePPedriniSAshtonNJ, et al.Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement2022; 18: 1141–1154.
37.
AggarwalRRanganathanP. Common pitfalls in statistical analysis: the use of correlation techniques. Perspect Clin Res2016; 7: 187–190.
38.
HuNTanMSYuJT, et al.Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients. J Alzheimers Dis2014; 38: 497–501.
39.
GuilleminGJ. Quinolinic acid, the inescapable neurotoxin. FEBS J2012; 279: 1356–1365.
40.
GarrisonAMParrottJMTunonA, et al.Kynurenine pathway metabolic balance influences microglia activity: targeting kynurenine monooxygenase to dampen neuroinflammation. Psychoneuroendocrinology2018; 94: 1–10.
41.
Cortes MalagonEMLopez OrnelasAOlvera GomezI, et al.The kynurenine pathway, aryl hydrocarbon receptor, and Alzheimer's disease. Brain Sci2024; 14: 950.
TingKKBrewBGuilleminG. The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotox Res2007; 12: 247–262.
44.
KiralyMFossJFGiordanoT. Neuroinflammation, its role in Alzheimer's disease and therapeutic strategies. J Prev Alzheimers Dis2023; 10: 686–698.
45.
NovoaCSalazarPCisternasP, et al.Inflammation context in Alzheimer's disease, a relationship intricate to define. Biol Res2022; 55: 39.
46.
WeberGEKoenigKAKhrestianM, et al.An altered relationship between soluble TREM2 and inflammatory markers in young adults with down syndrome: a preliminary report. J Immunol2020; 204: 1111–1118.
47.
WeberGEKhrestianMTuasonED, et al.Peripheral sTREM2-related inflammatory activity alterations in early-stage Alzheimer's disease. J Immunol2022; 208: 2283–2299.
48.
DeczkowskaAWeinerAAmitI. The physiology, pathology, and potential therapeutic applications of the TREM2 signaling pathway. Cell2020; 181: 1207–1217.
49.
ParkSHLeeEHKimHJ, et al.The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease. Sci Rep2021; 11: 13050.
50.
MaLAllenMSakaeN, et al.Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains. Mol Neurodegener2016; 11: 72.
51.
HooliBVParradoARMullinK, et al.The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology2014; 83: 1353–1358.
52.
ZhouSLTanCCHouXH, et al.TREM2 Variants and neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimers Dis2019; 68: 1171–1184.
53.
LillCMRengmarkAPihlstromL, et al.The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement2015; 11: 1407–1416.
54.
CruchagaCKauweJSHarariO, et al.GWAS Of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron2013; 78: 256–268.
55.
JinSCBenitezBAKarchCM, et al.Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet2014; 23: 5838–5846.
56.
CuyversEBettensKPhiltjensS, et al.Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging2014; 35: 726 e711–729.
57.
YehFLWangYTomI, et al.TREM2 Binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron2016; 91: 328–340.
58.
ZhongLChenXFWangT, et al.Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med2017; 214: 597–607.
59.
EllisKABushAIDarbyD, et al.The Australian imaging, biomarkers and lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr2009; 21: 672–687.
60.
MuellerSGWeinerMWThalLJ, et al.The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am2005; 15: 869–877. xi-xii.
61.
AyerAHWojtaKRamosEM, et al.Frequency of the TREM2 R47H variant in various neurodegenerative disorders. Alzheimer Dis Assoc Disord2019; 33: 327–330.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
